Redbud Medicine Secures $10M Series A Funding Led by Juming Ventures and Delian Capital, with Haoyue Capital as Exclusive Financial Advisor

VCBeat has learned that Redbud Medicine (Redbud Med), a leading international clinical CRO company, recently completed a tens-of-millions-of-US-dollars Series A financing round. The round was co-led by Juming Ventures and Delian Capital, with existing shareholder Hongfeng Capital continuing to increase its investment. Haoyue Capital served as the exclusive financial advisor.The proceeds from this financing round will be primarily used to accelerate customer acquisition in the Chinese market, build overseas teams, and attract talent, thereby positioning the company as the preferred clinical partner for Chinese innovative drugs going global.

Redbud Med was established in 2019. The company is currently headquartered in the Washington, D.C. area of the United States, with subsidiaries in Beijing, Shanghai, and Ningbo, China. It is led by an executive team with extensive international experience.The founder previously served as the Global Head of Clinical Development for New Drugs at a senior multinational corporation (MNC), Head of Clinical Operations at a leading international CRO, and Review Expert for Product Launches at an international pharmaceutical regulatory agency.。

Driven by both internal and external factors—namely, the urgent need for Chinese enterprises to tap into the potential of overseas markets, the growing strength of China’s innovative drug sector, the persistent pressure to reduce drug prices domestically, and the increasing alignment of China’s regulatory framework with international standards—products and teams with robust core competencies will increasingly expand beyond China’s borders to compete in the global marketplace.Chinese enterprises expanding overseas face challenges such as formulating overseas clinical development strategies, selecting overseas clinical resources (PIs and sites), understanding overseas regulatory requirements for registration, and ensuring effective collaboration within clinical operations teams.Therefore, full-service CRO partners with in-house clinical medicine and operations teams in both China and overseas, capable of establishing robust operational and communication systems, are the optimal choice for Chinese innovative pharmaceutical companies expanding into global markets.

The core members of Redbud Medicine’s management team have an average of over 20 years of industry experience, boasting extensive international perspectives and access to top-tier global clinical experts. With self-established operational teams in China and overseas, the company provides full-service clinical CRO solutions covering the entire process for innovative pharmaceutical enterprises.Redbud Medicine leverages an innovative dual-track PM operating mechanism to seamlessly coordinate global multicenter clinical trials across multiple countries and regions.The company specializes in real-time data analysis during innovation and clinical trials, providing innovative and efficient clinical development services to biotechnology enterprises in China and around the world. It helps domestic Chinese biotech companies bring their products to global markets and assists foreign biotech firms in introducing their products into China. Leveraging a robust international network of physicians and experts, the company enables rapid, one-stop global clinical trial registration and regulatory submissions, as well as the effective implementation of clinical operations strategies.

Ms. Fu Meng, Founder and CEO of Redbud MedicineRedbud Medicine expressed its delight at securing consecutive support from professional investment institutions throughout the year. The company extended its gratitude to Legend Star, the investor from the previous round, for its steadfast support, and to Hongfeng Capital, an existing shareholder, for increasing its stake in this financing round. Redbud Medicine remains firmly optimistic about the innovative capabilities of domestic Chinese enterprises. With the tripartite support of talent, capital, and policy, Chinese innovative pharmaceutical companies are poised to penetrate the major markets of Europe and the United States. Together with investors who have consistently believed in the innovative potential of China’s pharmaceutical sector, Redbud Medicine is committed to advancing the internationalization of Chinese innovative drugs. Furthermore, by facilitating overseas biotech companies to conduct early-stage clinical trials in China, the company aims to further engage local clinical resources in global early-stage innovation.

Dr. Cao Xianhua, Founder and Chairman of Redbud MedicineRedbud Medicine stated that it is committed to becoming the global R&D “brain” for biotech companies by making continuous investments in specialized disciplines such as early translational science, clinical medicine, statistical analysis, and regulatory science. Successful clinical development of innovative drugs requires close interdisciplinary collaboration, which addresses an urgent unmet need in the current market. We are honored to share a common vision with both new and existing shareholders regarding the global expansion of China’s innovative pharmaceuticals. Following this round of financing, we will further strengthen our investment in talent, striving to serve as a dedicated partner in facilitating the internationalization of China’s innovative drugs.

Dr. Shi Yongling, Partner at Juming Venture CapitalIt was stated that the global expansion of innovative drugs developed in China is a clear industry trend; however, only a very small number of pharmaceutical companies possess global clinical development capabilities. Consequently, numerous biotech firms urgently require professional clinical CROs to provide integrated international clinical development services. As an innovative drug clinical CRO with international operational capabilities, Redbud Medicine focuses on serving biotech companies both domestically and abroad. Its founding team boasts extensive experience in new drug clinical development and regulatory review in both China and the United States, along with access to robust top-tier international clinical resources. This enables the company to better help clients mitigate clinical development risks, formulate integrated product registration and filing strategies, and facilitate the international commercialization of their products. VCBeat Capital is honored to have the opportunity to partner with Redbud Medicine to jointly support the development of Chinese biotech companies.

Mr. He Xiaopeng, Investment Director at Delian CapitalIt stated that Delian Capital is optimistic about the major trend of domestic innovative drugs gradually entering the international arena. The formulation of scientific clinical strategies, efficient communication with mainstream overseas regulatory authorities, rapid initiation of clinical trial sites and subject enrollment, as well as standardized execution of clinical trials will become new requirements for clinical trials conducted by domestic innovative pharmaceutical companies. Leveraging the founders’ forward-looking insights and solid accumulation in the sector, Redbud Medicine has built a full-process, world-class team overseas and in China, focusing on the two core aspects of clinical trials: medical affairs and operations. Clinical trial projects for multiple partners are currently being advanced efficiently overseas. We look forward to Redbud Medicine’s continued growth and expansion, providing scientific, efficient, standardized, and reliable end-to-end clinical trial services to clients both domestically and internationally, thereby facilitating the market launch of more innovative drugs.

Mr. Guo Yixin, Managing Director of Haoyue CapitalIt is stated that internationalization is the core competitiveness in the second half of the clinical CRO industry. Chinese pharmaceutical companies urgently need teams with an international perspective, extensive clinical resources, and operational experience to provide end-to-end services. We believe that Redbud Medicine has the potential to rapidly establish barriers through its overseas business and become a premier clinical CRO. We are firmly convinced that as the company further expands its world-class international CRO team, it will ultimately grow into a globally leading international CRO.

Juming Ventures focuses on early-stage venture capital in the life sciences sector. Since its establishment in 2018, it has invested in over 40 startups spanning innovative drugs, biotechnology, and medical devices (including diagnostics). Juming Ventures remains grounded in China while addressing global clinical pain points, dedicated to partnering with outstanding enterprises by providing comprehensive services and supporting entrepreneurs throughout their growth journey.

DeLian Capital, established in 2011, has remained focused on the technology and innovative healthcare sectors, with an emphasis on early-stage, technology-driven projects. Its investment scope covers sub-sectors such as semiconductors, intelligent equipment, cloud-native technologies, novel therapies, and IBAT. The firm has invested in over 100 companies, including Maxic Semiconductor, ChipSolutions, Nanjing Hongtai, Yingchuang Huizhi, Rokae Technology, Mech-Mind, Fit2Cloud, Venus Medtech, Amunix, Gaocheng Biology, Zhishan Weixin, and ChenAn Bio.

Haoyue Capital, established in January 2014, is a leading industry-focused investment bank in China specializing in the healthcare sector. Headquartered in Shanghai, the firm maintains regional offices in Beijing and Shenzhen. Committed to empowering growth through capital and research-driven insights, Haoyue Capital helps outstanding Chinese healthcare companies successfully access capital markets, thereby creating value-added benefits for its clients. The partnership team comprises senior investment bankers with extensive experience in China’s healthcare sector, supported by a professional team of over 70 members. Haoyue Capital closely monitors dynamics and trends in the healthcare investment market, with its research and transaction coverage spanning multiple sub-sectors, including biopharmaceuticals, innovative medical devices, IVD and life sciences, health services, and smart healthcare. In 2021, Haoyue Capital completed more than 50 complex transactions involving private financing, M&A integration, and spin-offs of listed companies, with a total transaction value amounting to tens of billions of RMB, securing a leading position across various healthcare sub-sectors.